Triple
T1169408
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Spinraza |
E24879
|
entity |
| Predicate | developedBy |
P73
|
FINISHED |
| Object | Ionis Pharmaceuticals |
E24882
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Ionis Pharmaceuticals | Statement: [Spinraza, developedBy, Ionis Pharmaceuticals]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Ionis Pharmaceuticals Context triple: [Spinraza, developedBy, Ionis Pharmaceuticals]
-
A.
Ionis Pharmaceuticals
chosen
Ionis Pharmaceuticals is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics using antisense technology.
-
B.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based therapeutics for genetically defined diseases.
-
C.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
D.
Gilead Sciences (board member)
Gilead Sciences is a major American biopharmaceutical company known for developing antiviral drugs, including treatments for HIV, hepatitis C, and other serious diseases.
-
E.
Eisai
Eisai is a Japanese pharmaceutical company known for developing treatments in neurology and oncology, including Alzheimer’s disease therapies.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69a494082a7c819095004f423f294a64 |
completed | March 1, 2026, 7:31 p.m. |
| NER | Named-entity recognition | batch_69a4bce821b481908bc278a3fa7973f4 |
completed | March 1, 2026, 10:25 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69ac668562788190ac5f8d081a46b2ee |
completed | March 7, 2026, 5:55 p.m. |
Created at: March 1, 2026, 7:45 p.m.